Skip to main content

Drug Interactions between peanut allergen powder and Tanamine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

chlorpheniramine pyrilamine

Applies to: Tanamine (chlorpheniramine / phenylephrine / pyrilamine) and Tanamine (chlorpheniramine / phenylephrine / pyrilamine)

MONITOR: Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination. Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome. Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation. Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures. Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients. Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia. In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.

MANAGEMENT: Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked. Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations. Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them. A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.

References

  1. Stadnyk AN, Glezos JD (1983) "Drug-induced heat stroke." Can Med Assoc J, 128, p. 957-9
  2. Zelman S, Guillan R (1970) "Heat stroke in phenothiazine-treated patients: a report of three fatalities." Am J Psychiatry, 126, p. 1787-90
  3. Mann SC, Boger WP (1978) "Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated." Am J Psychiatry, 135, p. 1097-100
  4. Warnes H, Lehmann HE, Ban TA (1967) "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J, 96, p. 1112-3
  5. Gershon S, Neubauer H, Sundland DM (1965) "Interaction between some anticholinergic agents and phenothiazines." Clin Pharmacol Ther, 6, p. 749-56
  6. Sarnquist F, Larson CP Jr (1973) "Drug-induced heat stroke." Anesthesiology, 39, p. 348-50
  7. Johnson AL, Hollister LE, Berger PA (1981) "The anticholinergic intoxication syndrome: diagnosis and treatment." J Clin Psychiatry, 42, p. 313-7
  8. Lee BS (1986) "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry, 47, p. 571
  9. Forester D (1978) "Fatal drug-induced heat stroke." JACEP, 7, p. 243-4
  10. Moreau A, Jones BD, Banno V (1986) "Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia." Can J Psychiatry, 31, p. 339-41
  11. Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA (1983) "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm, 2, p. 174-8
  12. Cohen MA, Alfonso CA, Mosquera M (1994) "Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952]." Am J Psychiatry, 151, p. 619-20
  13. (2001) "Product Information. Cogentin (benztropine)." Merck & Co., Inc
  14. Kulik AV, Wilbur R (1982) "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry, 6, p. 75-82
  15. (2001) "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories
View all 15 references

Switch to consumer interaction data

Moderate

chlorpheniramine peanut allergen extract

Applies to: Tanamine (chlorpheniramine / phenylephrine / pyrilamine) and peanut allergen powder

MONITOR: Monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), catechol-O-methyltransferase (COMT) inhibitors, thyroid hormone, antihistamines, cardiac glycosides (e.g. digoxin) and diuretics may potentiate the response to epinephrine, including fatal consequences, in the treatment of serious systemic reactions that may occur during immunotherapy with allergenic extracts. Vasoconstricting and hypertensive effects may be potentiated by MAOIs, tricyclic antidepressants, and COMT inhibitors. Arrhythmogenic effects may be potentiated by thyroid hormones, antihistamines, cardiac glycosides and diuretics.

MANAGEMENT: Immunotherapy with allergenic extracts may not be appropriate in patients receiving MAOIs, tricyclic antidepressants, COMT inhibitors, thyroid hormone, antihistamines and cardiac glycosides as these patients may experience an exaggerated response to the usual doses of epinephrine required to reverse a systemic reaction.

References

  1. (2014) "Product Information. Grastek (timothy grass pollen allergen extract)." Merck & Co., Inc
  2. (2014) "Product Information. Ragwitek (ragweed pollen allergen extract)." Merck & Co., Inc
  3. (2014) "Product Information. Oralair (mixed grass pollens allergen extract)." Greer Laboratories Inc
  4. Cerner Multum, Inc. (2015) "Canadian Product Information."
  5. (2023) "Product Information. Palforzia (peanut allergen extract)." Aimmune Therapeutics
  6. (2022) "Product Information. Palforzia Level 1 (peanut allergen extract)." Aimmune Therapeutics UK Ltd
View all 6 references

Switch to consumer interaction data

Moderate

pyrilamine peanut allergen extract

Applies to: Tanamine (chlorpheniramine / phenylephrine / pyrilamine) and peanut allergen powder

MONITOR: Monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), catechol-O-methyltransferase (COMT) inhibitors, thyroid hormone, antihistamines, cardiac glycosides (e.g. digoxin) and diuretics may potentiate the response to epinephrine, including fatal consequences, in the treatment of serious systemic reactions that may occur during immunotherapy with allergenic extracts. Vasoconstricting and hypertensive effects may be potentiated by MAOIs, tricyclic antidepressants, and COMT inhibitors. Arrhythmogenic effects may be potentiated by thyroid hormones, antihistamines, cardiac glycosides and diuretics.

MANAGEMENT: Immunotherapy with allergenic extracts may not be appropriate in patients receiving MAOIs, tricyclic antidepressants, COMT inhibitors, thyroid hormone, antihistamines and cardiac glycosides as these patients may experience an exaggerated response to the usual doses of epinephrine required to reverse a systemic reaction.

References

  1. (2014) "Product Information. Grastek (timothy grass pollen allergen extract)." Merck & Co., Inc
  2. (2014) "Product Information. Ragwitek (ragweed pollen allergen extract)." Merck & Co., Inc
  3. (2014) "Product Information. Oralair (mixed grass pollens allergen extract)." Greer Laboratories Inc
  4. Cerner Multum, Inc. (2015) "Canadian Product Information."
  5. (2023) "Product Information. Palforzia (peanut allergen extract)." Aimmune Therapeutics
  6. (2022) "Product Information. Palforzia Level 1 (peanut allergen extract)." Aimmune Therapeutics UK Ltd
View all 6 references

Switch to consumer interaction data

Drug and food interactions

Major

peanut allergen extract food

Applies to: peanut allergen powder

ADJUST DOSING INTERVAL: Coadministration of peanut allergen extract with alcohol may potentiate the risk of allergic reactions, including anaphylaxis. According to some studies, alcohol is an augmenting factor influencing immunological mechanisms that can induce more severe allergic reactions and is involved in up to 15% of cases of anaphylactic reactions. Proposed mechanisms include an increase in allergen absorption from altered permeability of the intestinal epithelial barrier, enhancing mast cell and basophil activation, and an increase in serum IgE concentrations. In addition, according to product labeling, administration of peanut allergen extract during a fasting state may potentiate the risk of allergic reactions, including anaphylaxis. The exact mechanism has not been elucidated.

MANAGEMENT: To minimize the risk of allergic reactions, including anaphylaxis, some authorities recommend alcohol not be consumed for 2 hours before, or 2 hours after taking peanut allergen extract. If alcohol cannot be avoided, withholding or decreasing peanut allergen dosage should be considered. Peanut allergen extract should also be administered with an evening meal and not within 2 hours of bedtime.

References

  1. (2023) "Product Information. Palforzia (peanut allergen extract)." Aimmune Therapeutics
  2. (2022) "Product Information. Palforzia Level 1 (peanut allergen extract)." Aimmune Therapeutics UK Ltd
  3. Munoz-Cano R, Pascal M, Araujo G, et al. (2023) Mechanisms, Cofactors, and Augmenting Factors Involved in Anaphylaxis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623009/pdf/fimmu-08-01193.pdf

Switch to consumer interaction data

Moderate

chlorpheniramine food

Applies to: Tanamine (chlorpheniramine / phenylephrine / pyrilamine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Moderate

pyrilamine food

Applies to: Tanamine (chlorpheniramine / phenylephrine / pyrilamine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Moderate

phenylephrine food

Applies to: Tanamine (chlorpheniramine / phenylephrine / pyrilamine)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
View all 7 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.